Christian Chryssos of Monmouth County’s Academy of Allied Health and Science in Neptune will take part in the National Brain Bee.

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...

Three classes of medications have been approved by the Food and Drug Administration (FDA) for the treatment of the cognitive symptoms of Alzheimer's. They include cholinesterase inhibitors, N-methyl D ...

New research suggests that the formation of stress granules, clumps of proteins and RNA under stress, is a potential root cause of Alzheimer's disease. These granules affect biological processes ...

Doctors often use antidepressants to manage the depression, anxiety and agitation that accompanies a diagnosis of dementia. Now, a new study suggests the use of antidepressants may hasten the ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment.

Learning a second language could help stave off dementia for many years, scientists have revealed. It's long been established that bilingual people develop dementia an average of 5.4 years later ...

There's no single test to diagnose dementia; it’s a process. You may go through several types of tests. The tests look at how your brain thinks or reasons (cognitive tests), functions ...

Parkinson’s can cause a condition called Parkinson’s disease dementia. This condition is marked by a decline in thinking, reasoning, and problem-solving. Parkinson’s disease is a progressive ...